U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C15H14O3
Molecular Weight 242.2704
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FENOPROFEN

SMILES

CC(c1cccc(c1)Oc2ccccc2)C(=O)O

InChI

InChIKey=RDJGLLICXDHJDY-UHFFFAOYSA-N
InChI=1S/C15H14O3/c1-11(15(16)17)12-6-5-9-14(10-12)18-13-7-3-2-4-8-13/h2-11H,1H3,(H,16,17)

HIDE SMILES / InChI

Description
Curator's Comment:: https://www.drugs.com/pro/fenoprofen.html

Fenoprofen is a propionic acid derivative with analgesic, antiinflammatory and antipyretic properties. Fenoprofen inhibits prostaglandin synthesis by decreasing the enzyme needed for biosynthesis. In patients with rheumatoid arthritis, the anti-inflammatory action of fenoprofen has been evidenced by relief of pain, increase in grip strength, and reductions in joint swelling, duration of morning stiffness, and disease activity (as assessed by both the investigator and the patient). In patients with osteoarthritis, the anti-inflammatory and analgesic effects of fenoprofen have been demonstrated by reduction in tenderness as a response to pressure and reductions in night pain, stiffness, swelling, and overall disease activity (as assessed by both the patient and the investigator). These effects have also been demonstrated by relief of pain with motion and at rest and increased range of motion in involved joints. In patients with rheumatoid arthritis and osteoarthritis, clinical studies have shown fenoprofen to be comparable to aspirin in controlling the aforementioned measures of disease activity, but mild gastrointestinal reactions (nausea, dyspepsia) and tinnitus occurred less frequently in patients treated with fenoprofen than in aspirin-treated patients. It is not known whether fenoprofen causes less peptic ulceration than does aspirin. In patients with pain, the analgesic action of fenoprofen has produced a reduction in pain intensity, an increase in pain relief, improvement in total analgesia scores, and a sustained analgesic effect. Indicated for relief of the signs and symptoms of rheumatoid arthritis and osteoarthritis. Also for the relief of mild to moderate pain.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
NALFON

Approved Use

NALFON is a nonsteroidal anti-inflammatory drug indicated for: • Relief of mild to moderate pain in adults. • Relief of the signs and symptoms of rheumatoid arthritis. • Relief of the signs and symptoms of osteoarthritis.

Launch Date

195696000000
Primary
NALFON

Approved Use

NALFON is a nonsteroidal anti-inflammatory drug indicated for: • Relief of mild to moderate pain in adults. • Relief of the signs and symptoms of rheumatoid arthritis. • Relief of the signs and symptoms of osteoarthritis.

Launch Date

195696000000
Primary
NALFON

Approved Use

NALFON is a nonsteroidal anti-inflammatory drug indicated for: • Relief of mild to moderate pain in adults. • Relief of the signs and symptoms of rheumatoid arthritis. • Relief of the signs and symptoms of osteoarthritis.

Launch Date

195696000000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
28.3 μg/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FENOPROFEN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
105.2 μg × h/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FENOPROFEN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3 h
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FENOPROFEN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
1%
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FENOPROFEN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Disc. AE: Reaction gastrointestinal, Reaction skin...
Other AEs: Dyspepsia, Nausea...
AEs leading to
discontinuation/dose reduction:
Reaction gastrointestinal (2%)
Reaction skin (1%)
Cardiovascular disorder (NOS) (0.5%)
Other AEs:
Dyspepsia (10%)
Nausea (7.7%)
Constipation (7%)
Vomiting (2.6%)
Abdominal pain (2%)
Diarrhea (1.8%)
Headache (8.7%)
Somnolence (8.5%)
Dizziness (6.5%)
Tremor (2.2%)
Confusion (1.4%)
Sweating increased (4.6%)
Pruritus (4.2%)
Rash (3.7%)
Tinnitus (4.5%)
Blurred vision (2.2%)
Hearing decreased (1.6%)
Palpitations (2.5%)
Nervousness (5.7%)
Asthenia (5.4%)
Peripheral edema (5%)
Dyspnea (2.8%)
Fatigue (1.7%)
Upper respiratory infection (1.5%)
Nasopharyngitis (1.2%)
Gastritis (<1%)
Ulcer peptic with perforation (<1%)
Ulcer peptic with perforation (<1%)
Gastrointestinal hemorrhage (<1%)
Anorexia (<1%)
Flatulence (<1%)
Dry mouth (<1%)
Blood in stool (<1%)
Alkaline phosphatase increased (<1%)
LDH increased (<1%)
SGOT increased (<1%)
Jaundice (<1%)
Cholestatic hepatitis (<1%)
Buccal mucosa aphthous ulceration (<1%)
Taste metallic (<1%)
Pancreatitis (<1%)
Atrial fibrillation (<1%)
Pulmonary edema (<1%)
Electrocardiogram change (<1%)
Supraventricular tachycardia (<1%)
Renal failure (<1%)
Dysuria (<1%)
Cystitis (<1%)
Hematuria (<1%)
Oliguria (<1%)
Azotemia (<1%)
Anuria (<1%)
Nephritis interstitial (<1%)
Nephrosis (<1%)
Acute papillary necrosis (<1%)
Angioedema (<1%)
Purpura (<1%)
Bruising (<1%)
Hemorrhage (<1%)
Thrombocytopenia (<1%)
Hemolytic anemia (<1%)
Aplastic anemia (<1%)
Agranulocytosis (<1%)
Pancytopenia (<1%)
Depression (<1%)
Disorientation (<1%)
Seizures (<1%)
Trigeminal neuralgia (<1%)
Burning tongue (<1%)
Diplopia (<1%)
Optic neuritis (<1%)
Exfoliative dermatitis (<1%)
Toxic epidermal necrolysis (<1%)
Stevens-Johnson syndrome (<1%)
Alopecia (<1%)
Anaphylaxis (<1%)
Urticaria (<1%)
Malaise (<1%)
Insomnia (<1%)
Tachycardia (<1%)
Personality change (<1%)
Lymphadenopathy (<1%)
Mastodynia (<1%)
Fever (<1%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Cardiovascular disorder (NOS) 0.5%
Disc. AE
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Reaction skin 1%
Disc. AE
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Nasopharyngitis 1.2%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Confusion 1.4%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Upper respiratory infection 1.5%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Hearing decreased 1.6%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Fatigue 1.7%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Diarrhea 1.8%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Dyspepsia 10%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Abdominal pain 2%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Reaction gastrointestinal 2%
Disc. AE
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Blurred vision 2.2%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Tremor 2.2%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Palpitations 2.5%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Vomiting 2.6%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Dyspnea 2.8%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Rash 3.7%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Pruritus 4.2%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Tinnitus 4.5%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Sweating increased 4.6%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Peripheral edema 5%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Asthenia 5.4%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Nervousness 5.7%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Dizziness 6.5%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Constipation 7%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Nausea 7.7%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Somnolence 8.5%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Headache 8.7%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Acute papillary necrosis <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Agranulocytosis <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Alkaline phosphatase increased <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Alopecia <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Anaphylaxis <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Angioedema <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Anorexia <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Anuria <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Aplastic anemia <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Atrial fibrillation <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Azotemia <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Blood in stool <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Bruising <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Buccal mucosa aphthous ulceration <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Burning tongue <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Cholestatic hepatitis <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Cystitis <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Depression <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Diplopia <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Disorientation <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Dry mouth <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Dysuria <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Electrocardiogram change <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Exfoliative dermatitis <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Fever <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Flatulence <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Gastritis <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Gastrointestinal hemorrhage <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Hematuria <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Hemolytic anemia <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Hemorrhage <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Insomnia <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Jaundice <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
LDH increased <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Lymphadenopathy <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Malaise <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Mastodynia <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Nephritis interstitial <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Nephrosis <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Oliguria <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Optic neuritis <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Pancreatitis <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Pancytopenia <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Personality change <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Pulmonary edema <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Purpura <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Renal failure <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
SGOT increased <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Seizures <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Stevens-Johnson syndrome <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Supraventricular tachycardia <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Tachycardia <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Taste metallic <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Thrombocytopenia <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Toxic epidermal necrolysis <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Trigeminal neuralgia <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Ulcer peptic with perforation <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Ulcer peptic with perforation <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
Urticaria <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
PubMed

PubMed

TitleDatePubMed
Pharmacodynamics, chiral pharmacokinetics, and pharmacokinetic-pharmacodynamic modeling of fenoprofen in patients with diabetes mellitus.
2006 Nov
Prophylaxis of migraine.
2006 Sep
Seasonality effects on pharmaceuticals and s-triazine herbicides in wastewater effluent and surface water from the Canadian side of the upper Detroit River.
2006 Sep
The aryl propionic acid R-flurbiprofen selectively induces p75NTR-dependent decreased survival of prostate tumor cells.
2007 Apr 1
Anti-inflammatory and immune therapy for Alzheimer's disease: current status and future directions.
2007 Dec
A tale of switched functions: from cyclooxygenase inhibition to M-channel modulation in new diphenylamine derivatives.
2007 Dec 26
Immunomodulatory effect of nonsteroidal anti-inflammatory drugs (NSAIDs) at the clinically available doses.
2007 Jan
Synthesis and in vitro antitumor effect of diclofenac and fenoprofen thiolated and nonthiolated polyaspartamide-drug conjugates.
2007 Jan
A peripatetic pediatrician's journey into pediatric rheumatology: Part II.
2007 Jun 21
Comparison of Prevention of NSAID-Induced Gastrointestinal Complications by Rebamipide and Misoprostol: A Randomized, Multicenter, Controlled Trial-STORM STUDY.
2007 Mar
Fenoprofen and ketoprofen amides as potential antitumor agents.
2007 Mar
Enantioseparation by CE with vancomycin as chiral selector: Improving the separation performance by dynamic coating of the capillary with poly(dimethylacrylamide).
2007 Mar
Traditional nonsteroidal anti-inflammatory drugs and postmenopausal hormone therapy: a drug-drug interaction?
2007 May
Rapid online-SPE-MS/MS method for ketoprofen determination in dermal interstitial fluid samples from rats obtained by microdialysis or open-flow microperfusion.
2007 May 1
Stereoselective disposition of fenoprofen in plasma and synovial fluid of patients with rheumatoid arthritis.
2007 May 5
Removal of selected pharmaceuticals and personal care products (PPCPs) and endocrine-disrupting chemicals (EDCs) during sand filtration and ozonation at a municipal sewage treatment plant.
2007 Nov
Removal of selected pharmaceuticals by chlorination, coagulation-sedimentation and powdered activated carbon treatment.
2008
Peroxisome proliferator-activated receptors in the modulation of the immune/inflammatory response in atherosclerosis.
2008
Role of peroxisome proliferator-activated receptor gamma and its ligands in the treatment of hematological malignancies.
2008
Sodium-coupled monocarboxylate transporters in normal tissues and in cancer.
2008
Efficient, selective, and green: catalyst tuning for highly enantioselective reactions of ethylene.
2008 Apr 17
A combination of statistical and analytical evaluation methods as a new optimization strategy for the quantification of pharmaceutical residues in sewage effluent.
2008 Apr 21
Chiral separation of fluvastatin enantiomers by capillary electrophoresis.
2008 Aug
Species differences in inhibition potential of nonsteroidal anti-inflammatory drugs against estradiol 3beta-glucuronidation between rats, dogs, and humans.
2008 Jul
Interactions between APP secretases and inflammatory mediators.
2008 Jun 18
The effect of piroxicam on the formation of postoperative, intraabdominal adhesion in rats.
2008 Oct
Robust open tubular layer of S-ketoprofen imprinted polymer for chiral LC separation.
2008 Sep
Evaluation of pharmaceuticals and personal care products as water-soluble molecular markers of sewage.
2008 Sep 1
Chemoenzymatic and microbial dynamic kinetic resolutions.
2009 Apr
Using subcritical/supercritical fluid chromatography to separate acidic, basic, and neutral compounds over an ionic liquid-functionalized stationary phase.
2009 Apr 17
Combined use of chiral ionic liquid and CD for MEKC: Part II. Determination of binding constants.
2009 Aug
The novel phosphoramidate derivatives of NSAID 3-hydroxypropylamides: synthesis, cytostatic and antiviral activity evaluations.
2009 Jan
Synthesis of dehydroabietic acid-modified chitosan and its drug release behavior.
2009 Jan 5
Antioxidant activity of NSAID hydroxamic acids.
2009 Jun
Synthesis and biological evaluation of O-methyl and O-ethyl NSAID hydroxamic acids.
2009 Oct
Ibuprofen-arginine generates nitric oxide and has enhanced anti-inflammatory effects.
2009 Oct
Aldosterone glucuronidation by human liver and kidney microsomes and recombinant UDP-glucuronosyltransferases: inhibition by NSAIDs.
2009 Sep
The Nuclear Receptor PPARgamma as a Therapeutic Target for Cerebrovascular and Brain Dysfunction in Alzheimer's Disease.
2010
PPARs in Irradiation-Induced Gastrointestinal Toxicity.
2010
Rapid simultaneous determination of four non-steroidal anti-inflammatory drugs by means of derivative nonlinear variable-angle synchronous fluorescence spectrometry.
2010 Aug
Enantiomeric separation of 2-arylpropionic acid nonsteroidal anti-inflammatory drugs by HPLC with hydroxypropyl-beta-cyclodextrin as chiral mobile phase additive.
2010 Aug
Sumatriptan-naproxen fixed combination for acute treatment of migraine: a critical appraisal.
2010 Feb 18
Occurrence and risk assessment of acidic pharmaceuticals in the Yellow River, Hai River and Liao River of north China.
2010 Jul 15
A protein-coated magnetic beads as a tool for the rapid drug-protein binding study.
2010 Jul 8
Cyclooxygenase Inhibitors, Aspirin and Ibuprofen, Inhibit MHC-restricted Antigen Presentation in Dendritic Cells.
2010 Jun
Risk factors of drug interaction between warfarin and nonsteroidal anti-inflammatory drugs in practical setting.
2010 Mar
Use of a robust dehydrogenase from an archael hyperthermophile in asymmetric catalysis-dynamic reductive kinetic resolution entry into (S)-profens.
2010 May 5
Primaquine-NSAID twin drugs: Synthesis, radical scavenging, antioxidant and Fe2+ chelating activity.
2010 Sep
Electrokinetic supercharging focusing in capillary zone electrophoresis of weakly ionizable analytes in environmental and biological samples.
2010 Sep
Evaluation of phenoxybenzamine in the CFA model of pain following gene expression studies and connectivity mapping.
2010 Sep 16
Patents

Sample Use Guides

In Vivo Use Guide
400 mg to 600 mg orally 3 or 4 times a day
Route of Administration: Oral
Name Type Language
FENOPROFEN
HSDB   INN   MI   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
(+/-)-M-PHENOXYHYDRATROPIC ACID
Systematic Name English
FENOPROFEN [WHO-DD]
Common Name English
NSC-757813
Code English
FENOPROFEN [VANDF]
Common Name English
3-PHENOXYHYDRATROPIC ACID
Systematic Name English
FENOPROFEN [INN]
Common Name English
FENOPROFEN [MI]
Common Name English
BENZENEACETIC ACID, .ALPHA.-METHYL-3-PHENOXY-
Systematic Name English
2-(M-PHENOXYPHENYL)PROPIONIC ACID
Systematic Name English
FENOPROFEN [HSDB]
Common Name English
FENOPROFEN [USAN]
Common Name English
DL-2-(3-PHENOXYPHENYL)PROPIONIC ACID
Common Name English
(+/-)-FENOPROFEN
Common Name English
2-(3-PHENOXYPHENYL)PROPIONIC ACID
Systematic Name English
LILLY-53858
Code English
Classification Tree Code System Code
NCI_THESAURUS C1323
Created by admin on Fri Jun 25 22:01:53 UTC 2021 , Edited by admin on Fri Jun 25 22:01:53 UTC 2021
WHO-ATC M01AE04
Created by admin on Fri Jun 25 22:01:53 UTC 2021 , Edited by admin on Fri Jun 25 22:01:53 UTC 2021
WHO-VATC QM01AE04
Created by admin on Fri Jun 25 22:01:53 UTC 2021 , Edited by admin on Fri Jun 25 22:01:53 UTC 2021
NDF-RT N0000175721
Created by admin on Fri Jun 25 22:01:53 UTC 2021 , Edited by admin on Fri Jun 25 22:01:53 UTC 2021
NDF-RT N0000175722
Created by admin on Fri Jun 25 22:01:53 UTC 2021 , Edited by admin on Fri Jun 25 22:01:53 UTC 2021
LIVERTOX 404
Created by admin on Fri Jun 25 22:01:53 UTC 2021 , Edited by admin on Fri Jun 25 22:01:53 UTC 2021
NDF-RT N0000000160
Created by admin on Fri Jun 25 22:01:53 UTC 2021 , Edited by admin on Fri Jun 25 22:01:53 UTC 2021
Code System Code Type Description
HSDB
3328
Created by admin on Fri Jun 25 22:01:53 UTC 2021 , Edited by admin on Fri Jun 25 22:01:53 UTC 2021
PRIMARY
WIKIPEDIA
FENOPROFEN
Created by admin on Fri Jun 25 22:01:53 UTC 2021 , Edited by admin on Fri Jun 25 22:01:53 UTC 2021
PRIMARY
CAS
31879-05-7
Created by admin on Fri Jun 25 22:01:53 UTC 2021 , Edited by admin on Fri Jun 25 22:01:53 UTC 2021
SUPERSEDED
PUBCHEM
3342
Created by admin on Fri Jun 25 22:01:53 UTC 2021 , Edited by admin on Fri Jun 25 22:01:53 UTC 2021
PRIMARY
EVMPD
SUB07578MIG
Created by admin on Fri Jun 25 22:01:53 UTC 2021 , Edited by admin on Fri Jun 25 22:01:53 UTC 2021
PRIMARY
ECHA (EC/EINECS)
249-770-1
Created by admin on Fri Jun 25 22:01:53 UTC 2021 , Edited by admin on Fri Jun 25 22:01:53 UTC 2021
PRIMARY
DRUG BANK
DB00573
Created by admin on Fri Jun 25 22:01:53 UTC 2021 , Edited by admin on Fri Jun 25 22:01:53 UTC 2021
PRIMARY
INN
3104
Created by admin on Fri Jun 25 22:01:53 UTC 2021 , Edited by admin on Fri Jun 25 22:01:53 UTC 2021
PRIMARY
ChEMBL
CHEMBL1297
Created by admin on Fri Jun 25 22:01:53 UTC 2021 , Edited by admin on Fri Jun 25 22:01:53 UTC 2021
PRIMARY
NCI_THESAURUS
C61760
Created by admin on Fri Jun 25 22:01:53 UTC 2021 , Edited by admin on Fri Jun 25 22:01:53 UTC 2021
PRIMARY
LACTMED
Fenoprofen
Created by admin on Fri Jun 25 22:01:53 UTC 2021 , Edited by admin on Fri Jun 25 22:01:53 UTC 2021
PRIMARY
EPA CompTox
29679-58-1
Created by admin on Fri Jun 25 22:01:53 UTC 2021 , Edited by admin on Fri Jun 25 22:01:53 UTC 2021
PRIMARY
FDA UNII
RA33EAC7KY
Created by admin on Fri Jun 25 22:01:53 UTC 2021 , Edited by admin on Fri Jun 25 22:01:53 UTC 2021
PRIMARY
CAS
29679-58-1
Created by admin on Fri Jun 25 22:01:53 UTC 2021 , Edited by admin on Fri Jun 25 22:01:53 UTC 2021
PRIMARY
ECHA (EC/EINECS)
250-850-3
Created by admin on Fri Jun 25 22:01:53 UTC 2021 , Edited by admin on Fri Jun 25 22:01:53 UTC 2021
ALTERNATIVE
DRUG CENTRAL
1154
Created by admin on Fri Jun 25 22:01:53 UTC 2021 , Edited by admin on Fri Jun 25 22:01:53 UTC 2021
PRIMARY
MESH
D005279
Created by admin on Fri Jun 25 22:01:53 UTC 2021 , Edited by admin on Fri Jun 25 22:01:53 UTC 2021
PRIMARY
MERCK INDEX
M5281
Created by admin on Fri Jun 25 22:01:53 UTC 2021 , Edited by admin on Fri Jun 25 22:01:53 UTC 2021
PRIMARY Merck Index
RXCUI
4331
Created by admin on Fri Jun 25 22:01:53 UTC 2021 , Edited by admin on Fri Jun 25 22:01:53 UTC 2021
PRIMARY RxNorm
IUPHAR
4820
Created by admin on Fri Jun 25 22:01:53 UTC 2021 , Edited by admin on Fri Jun 25 22:01:53 UTC 2021
PRIMARY